Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia

Tyrosine kinases inhibitors (TKIs) revolutionized chronic myeloid leukemia (CML) treatment for many years, prolonging patients’ life expectancy to be comparable to age-matched healthy individuals. According to the latest the European LeukemiaNet (ELN) recommendations, CML treatment aims to achieve l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwaśnik, Paulina, Giannopoulos, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399881/
https://www.ncbi.nlm.nih.gov/pubmed/34442340
http://dx.doi.org/10.3390/jpm11080697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399881/
https://www.ncbi.nlm.nih.gov/pubmed/34442340
http://dx.doi.org/10.3390/jpm11080697

Ejemplares similares